Patent: US 12,239,739 B2
Filed: March 22, 2019
Assignee: Novo Nordisk A/S
What the Patent Covers
This U.S. patent claims methods and dosing regimens for orally administering a GLP-1 peptide (such as semaglutide, the active ingredient in Rybelsus) in a solid oral dosage form in combination with an enhancer, tailored to provide therapeutic treatment for conditions like type 2 diabetes and weight management.
Key technical aspects include:
- GLP-1 peptide with a long plasma half-life (≥60 hours) in humans, which makes holding effective plasma levels more predictable through an oral regimen rather than injections.
- Dosing methods where the peptide is administered more frequently relative to its half-life to reduce variability in blood levels and improve clinical outcomes.
- The solid composition may include enhancers that boost oral bioavailability — a major hurdle for peptide drugs like GLP-1s.
This kind of invention supports the commercial utility of oral semaglutide products like Rybelsus, which have carved out a unique market niche (being among the first oral GLP-1 receptor agonists) compared with injectable alternatives.
Why It’s Lucrative and Important
1. Part of the Semaglutide Franchise Backbone
Novo’s semaglutide class (including Ozempic for diabetes, Wegovy for obesity, and Rybelsus for oral diabetes treatment) has been one of the highest-revenue product lines in the industry, with combined global sales reaching tens of billions annually. The ability to administer GLP-1 therapies orally expands patient access and market share, compared with injectable formulations.
2. Intellectual Property “Thicket” Strategy
In addition to core compound patents on semaglutide itself, Novo has secured follow-on patents on dosing regimens, formulations, and delivery methods. These help extend exclusivity, delay generic competition, and secure pricing power — critical factors in blockbuster drug profitability.
3. Supports Long-Term Market Protection
While initial compound patents have high strategic value, formulation and method patents support broader and longer-lasting protection — often extending the effective commercial life of products like Rybelsus beyond first approvals.
Summary
The US 12,239,739 B2 patent is a strategically important filing for Novo Nordisk because it protects core methods of administering long-acting GLP-1 peptides orally — technology foundational to the success of Rybelsus and supplemental to the company’s global semaglutide franchise. This kind of IP strengthens Novo’s position in the highly lucrative diabetes and obesity treatment markets by broadening how its therapies can be used and sustaining exclusivity in key geographies.
BioTech IP Review 
Leave a comment